Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis

201925 citationsJournal Articlegold Open Access

Authors

Mehdi Javanbakht · The Medical Device (United Kingdom)

Miranda Trevor · Newcastle University

Mohsen Rezaei Hemami‬ · University of Exeter

Kazem Rahimi · The George Institute for Global Health

Michael Branagan-Harris · University of Southampton

Fabian Degener · CytoSorbents (Germany)

Daniel Adam

Abstract

The implementation of CytoSorb as an intraoperative intervention for patients receiving ticagrelor undergoing emergent or urgent cardiac surgery is a cost-saving strategy, yielding improvement in perioperative and postoperative outcomes and decreased health resource use.

Topics & Keywords

Antiplatelet Therapy and Cardiovascular Diseases Lipoproteins and Cardiovascular Health Cardiac, Anesthesia and Surgical Outcomes

Publication Details

Published in: PharmacoEconomics - Open

Volume 4, Issue 2, pp. 307-319

DOI: 10.1007/s41669-019-00183-w

Field-Weighted Citation Impact: 1.77

Command Palette

Ticagrelor Removal by CytoSorb® in Patients Requiring Emergent or Urgent Cardiac Surgery: A UK-Based Cost-Utility Analysis

Authors

Abstract

Topics & Keywords

Publication Details